Exclusive CFN Media Interview: RISE Life Science Study on Cannabis and Sexual Health (Part 2)

CFN Media recently sat down with Dr. Regina Nelson, who is leading a long-term study of sexual health and wellness and how it relates to cannabis for RISE Life Science Corp. (CSE: RLSC). Dr. Nelson is a noted U.S.- based advocate for medical cannabis and author of many peer-reviewed research papers and books on the subject. She is also a founding officer of The eCS Therapy Center, a non-profit organization building awareness of the endocannabinoid system.

Dr. Nelson is working with RISE Life Science to implement a broad and long-term study called ‘The RISE Report on Cannabis and Sexual Health and Wellness’. RISE Life Science is developing and commercializing cannabis-based products for sexual health and wellness. The company is pioneering new and innovative products in an emerging category created by the legalization of cannabis.

This article is Part 2 of a two-story series on her work with Rise Life Science Corp. Click here to read Part 1.

1. The protocols for the study are being validated by the Biomedical Research Alliance of New York (BRANY). What is this organization and why is the validation important for the RISE Report?

BRANY is an Institutional Review Board and is reviewing “Sexual Health and Cannabis: A Quantitative and Qualitative Analysis of Consumers of Novel Cannabis Products,” a study which will be published as “The RISE Report.” The IRB validates the study does no harm to human participants. Given the sensitive nature of the subject matter, sexual function and health and cannabis use, an acknowledgement of informed consent will be required for all participants.

The study and questionnaire are expected to receive BRANY Institutional Review Board approval shortly.

2. An advisory board has been created for the RISE Report. Who is on it and how will the board assist you?

Yes, the names of those on the Board will be announced shortly. You can expect to see academics, scientists, and other industry leaders.

3. How does a study of this type relate to clinical trials for medical products?

This type of study will help us learn more than clinical trials for a specific medical product. At this point in time, millions of people are currently using cannabis products, but no one is talking to them. The data we collect through this study will be meaningful.

4. What is the timeline for launching and completing the study? Do you plan to publish the results?

The study will beta-test this summer with a small group of participants. The study will launch in mid-September 2018. Beginning in 2019, participants will be able to view immediate results in many areas and quarterly reports will be released through the RISE Report.

5. How can RISE Life Science use this study in its own research and development efforts?

Through this study, RISE will be able to more clearly understand the various factors that affect healthy sexual function and experiences. This study will do that, and it will also help us learn how the introduction of innovative and emerging cannabis products affect sexual experiences, function, and health.

Through this proprietary study RISE will collect information on:

• What sexual function or health concerns are affecting participants
• What experiences are particularly important and why
• How novel cannabis products affect experiences and sexual outcomes
• Specific differences in affect across genders
• Sexual experiences of participants using cannabis products

This is all very valuable to informing product development. The fact that a study of this size has never before been undertaken is significant and it will certainly translate into a competitive advantage for RISE Life Science.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

About Robin Lefferts